AI
UTHR icon

Analytic Investors’s United Therapeutics UTHR Stock Holding History

Analytic Investors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$47.5M Sell
402,511
-112,840
-22% -$13.6M 0.53% 54
2016
Q2 		$54.6M Buy
515,351
+208,036
+68% +$23.2M 0.65% 47
2016
Q1 		$34.2M Buy
307,315
+38,384
+14% +$4.86M 0.42% 68
2015
Q4 		$42.1M Buy
268,931
+245,233
+1,035% +$35.7M 0.53% 50
2015
Q3 		$3.11M Buy
23,698
+12,681
+115% +$2.03M 0.04% 239
2015
Q2 		$1.92M Sell
11,017
-218
-2% -$39.2K 0.03% 288
2015
Q1 		$1.94M Buy
11,235
+7,853
+232% +$1.2M 0.03% 276
2014
Q4 		$438K Sell
3,382
-18,335
-84% -$2.36M 0.01% 434
2014
Q3 		$2.79M Sell
21,717
-15,578
-42% -$1.61M 0.04% 222
2014
Q2 		$3.3M Buy
37,295
+17,658
+90% +$1.7M 0.05% 204
2014
Q1 		$1.85M Sell
19,637
-14,086
-42% -$1.44M 0.03% 296
2013
Q4 		$3.81M Buy
33,723
+16,037
+91% +$1.45M 0.06% 194
2013
Q3 		$1.4M Sell
17,686
-3,701
-17% -$271K 0.02% 276
2013
Q2 		$1.41M Buy
+21,387
New +$1.38M 0.02% 323

Other funds holding UTHR

SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Analytic Investors's UTHR Position: Q3 2016 in Review

Analytic Investors reduced its United Therapeutics (UTHR) stake by 22% in Q3 2016, selling an estimated $13.6M and leaving 402,511 shares worth $47.5M. The position accounts for 0.53% of the portfolio, ranked #54.

Analytic Investors first reported a position in UTHR in Q2 2013 and has held it in 14 quarters since. The position peaked at $54.6M in Q2 2016. 395 funds tracked by Wall St. Rank hold UTHR as of Q3 2016.

  • Analytic Investors held 402,511 shares of United Therapeutics worth $47.5M as of Q3 2016.
  • Analytic Investors sold 112,840 United Therapeutics shares in Q3 2016, an estimated $13.6M.
  • United Therapeutics made up 0.53% of Analytic Investors's portfolio in Q3 2016, its #54 holding.
  • Analytic Investors first reported a position in United Therapeutics in Q2 2013 and has held it in 14 quarters since.
  • Analytic Investors's United Therapeutics position peaked at $54.6M in Q2 2016.
  • 395 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2016.

Based on Analytic Investors's 13F filing for Q3 2016, filed 14 Nov 2016.